How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy?

  • Patricia Maningat
  • Bruce R. Gordon
  • Jan L. Breslow
Statin Drugs (MB Clearfield, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Statin Drugs


Statins are highly effective drugs prescribed to millions of people to lower LDL-cholesterol and decrease cardiovascular risk. The benefits of statin therapy seen in randomized clinical trials will only be replicated in real-life if patients adhere to the prescribed treatment regimen. But, about half of patients discontinue statin therapy within the first year, and adherence decreases with time. Patient, physician and healthcare system-related factors play a role in this problem. Recent studies have focused more on the patients’ perspectives on non-adherence. Adverse events are cited as the most common cause of statin discontinuation; thus, the healthcare provider must be willing to ally and dialogue with patients to address concerns and assess the risks and benefits of continued statin therapy.


Statin Adherence Compliance Patient–physician communication Adverse events Lipid-lowering 



No potential conflicts of interest relevant to this article were reported.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–220.PubMedCrossRefGoogle Scholar
  2. 2.
    Cutler DM, Everett W. Thinking outside the pillbox—medication adherence as a priority for health care reform. N Engl J Med. 2010;362(17):1553–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–7.PubMedCrossRefGoogle Scholar
  4. 4.
    •• Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15. This large internet-based survey provides insights into the behavior and attitudes of current and former statin users. More effective dialogue between patients and healthcare providers may increase persistence of statin use, specially when the patient is concerned about adverse events.PubMedCrossRefGoogle Scholar
  5. 5.
    Charland S, Agatep B, Epstein R, et al. Patient knowledge of pharmacogenetic information improves adherence to statin therapy: results of the additional KIF6 risk offers better adherence to statins (AKROBATS) trial. JACC. 2012;59(13):E1848.Google Scholar
  6. 6.
    • Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev. 2010;3:CD004371. This review showed that the most promising intervention to increase adherence to lipid lowering drugs includes strategies to remind patients about their medications.Google Scholar
  7. 7.
    Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005–16.PubMedCrossRefGoogle Scholar
  8. 8.
    Downs JR, Clearfield M, Tyroler HA, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol. 2001;87(9):1074–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720–32.PubMedCrossRefGoogle Scholar
  10. 10.
    MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7–22.Google Scholar
  11. 11.
    Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383–1389.Google Scholar
  12. 12.
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med 2008.Google Scholar
  13. 13.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–7.PubMedCrossRefGoogle Scholar
  14. 14.
    • Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90. This meta analysis showed that even in individuals considered to be at low risk for CV disease, LDL cholesterol reduction results in reduction in major vascular events. These individuals would not be treated under present guidelines.PubMedGoogle Scholar
  15. 15.
    Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.PubMedCrossRefGoogle Scholar
  16. 16.
    Superko HR, Roberts R, Agatston A, et al. Genetic testing for early detection of individuals at risk of coronary heart disease and monitoring response to therapy: challenges and promises. Curr Atheroscler Rep. 2011;13(5):396–404.PubMedCrossRefGoogle Scholar
  17. 17.
    Gotto Jr AM, Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol. 2012;110(1 Suppl):3A–14.PubMedCrossRefGoogle Scholar
  18. 18.
    Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother. 2008;42(9):1208–15.PubMedCrossRefGoogle Scholar
  19. 19.
    Stagnitti M. Trends in Statins Utilization and Expenditures for the U.S. Civilian Noninstitutionalized Population, 2000 and 2005. Statistical Brief #205. In. Edited by Quality AfHRa, vol. 2011. Rockville, MD; 2008.Google Scholar
  20. 20.
    (CDC) CfDCaP: Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol—United States, 1999–2002 and 2005–2008. MMWR Morb Mortal Wkly Rep 2011;60(4):109–114.Google Scholar
  21. 21.
    Spatz ES, Canavan ME, Desai MM. From here to JUPITER: identifying new patients for statin therapy using data from the 1999–2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcome. 2009;2(1):41–8.CrossRefGoogle Scholar
  22. 22.
    Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011;5(5):338–67.PubMedCrossRefGoogle Scholar
  23. 23.
    Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122(1):198–208.PubMedCrossRefGoogle Scholar
  24. 24.
    AIM-HIGH, Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J 2011;161(3):471–477 e472.Google Scholar
  25. 25.
    Maningat P, Breslow JL. Needed: pragmatic clinical trials for statin-intolerant patients. N Engl J Med. 2011;365(24):2250–1.PubMedCrossRefGoogle Scholar
  26. 26.
    Buse JB, Bigger JT, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99(12A):21i–33.PubMedCrossRefGoogle Scholar
  27. 27.
    Scott R, Best J, Forder P, et al. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol. 2005;4:13.PubMedCrossRefGoogle Scholar
  28. 28.
    Ebrahim S, Casas JP. Statins for all by the age of 50 years? Lancet. 2012;380(9841):545–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999–2006. JAMA. 2009;302(19):2104–10.PubMedCrossRefGoogle Scholar
  30. 30.
    Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410–21.PubMedCrossRefGoogle Scholar
  31. 31.
    Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455–61.PubMedCrossRefGoogle Scholar
  32. 32.
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143–3421.Google Scholar
  33. 33.
    Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167(8):847–52.PubMedCrossRefGoogle Scholar
  34. 34.
    Cutrona SL, Choudhry NK, Fischer MA, et al. Targeting cardiovascular medication adherence interventions. J Am Pharm Assoc (2003) 2012;52(3):381–397.Google Scholar
  35. 35.
    Calvert SB, Kramer JM, Anstrom KJ, et al. Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial. Am Heart J 2012;163(4):657–665 e651.Google Scholar
  36. 36.
    Gomez Sandoval YH, Braganza MV, Daskalopoulou SS. Statin discontinuation in high-risk patients: a systematic review of the evidence. Curr Pharm Des. 2011;17(33):3669–89.PubMedCrossRefGoogle Scholar
  37. 37.
    Aubert RE, Yao J, Xia F, Garavaglia SB. Is there a relationship between early statin compliance and a reduction in healthcare utilization? Am J Manag Care. 2010;16(6):459–66.PubMedGoogle Scholar
  38. 38.
    • Shroufi A, Powles JW. Adherence and chemoprevention in major cardiovascular disease: a simulation study of the benefits of additional use of statins. J Epidemiol Community Health. 2010;64(2):109–13. This is a simulation study showing that improving adherence to statin therapy rather than lowering the CV risk threshold for initiating statin therapy would prevent twice as many additional deaths.PubMedCrossRefGoogle Scholar
  39. 39.
    Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203–12.PubMedCrossRefGoogle Scholar
  40. 40.
    Lamberts EJ, Nijpels G, Welschen LM, et al. Discontinuation of statins among patients with type 2 diabetes. Diabetes Metab Res Rev. 2012;28(3):241–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Bell KJ, Kirby A, Hayen A, Irwig L, Glasziou P. Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data. BMJ. 2011;342:d12.PubMedCrossRefGoogle Scholar
  42. 42.
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.PubMedCrossRefGoogle Scholar
  43. 43.
    Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–35.PubMedCrossRefGoogle Scholar
  44. 44.
    Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–14.PubMedCrossRefGoogle Scholar
  45. 45.
    Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care. 2010;48(3):196–202.PubMedCrossRefGoogle Scholar
  46. 46.
    Adams JR, Elwyn G, Legare F, Frosch DL. Communicating with physicians about medical decisions: a reluctance to disagree. Arch Intern Med. 2012;172(15):1184–6.PubMedGoogle Scholar
  47. 47.
    Ma J, Sehgal NL, Ayanian JZ, Stafford RS. National trends in statin use by coronary heart disease risk category. PLoS Med. 2005;2(5):e123.PubMedCrossRefGoogle Scholar
  48. 48.
    Lattry P, Molimard M, Dedieu B: Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study. BMC 2011.Google Scholar
  49. 49.
    Fung V, Sinclair F, Wang H, et al. Patients' perspectives on nonadherence to statin therapy: a focus-group study. Perm J. 2010;14(1):4–10.PubMedGoogle Scholar
  50. 50.
    Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29(7):800–11.PubMedCrossRefGoogle Scholar
  51. 51.
    Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373–418.PubMedCrossRefGoogle Scholar
  52. 52.
    Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42.PubMedCrossRefGoogle Scholar
  53. 53.
    FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. In: FDA Drug Safety Communication. 2012.Google Scholar
  54. 54.
    FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. In: FDA Drug Safety Communication. 2011.Google Scholar
  55. 55.
    • Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565–71. Further analysis of the JUPITER study shows that new-onset diabetes develops in the group already at high risk of developing diabetes.PubMedCrossRefGoogle Scholar
  56. 56.
    Standards of medical care in diabetes—2012. Diabetes Care 2012;35 Suppl 1:S11–63.Google Scholar
  57. 57.
    Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171(9):814–22.PubMedCrossRefGoogle Scholar
  58. 58.
    Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation. 2009;119(3):390–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Gossey JT, Whitney SN, Crouch MA, et al. Promoting knowledge of statins in patients with low health literacy using an audio booklet. Patient Prefer Adherence. 2011;5:397–403.PubMedGoogle Scholar
  60. 60.
    Eussen SR, de Jong N, Rompelberg CJ, et al. Effects of the use of phytosterol/-stanol-enriched margarines on adherence to statin therapy. Pharmacoepidemiol Drug Saf. 2010;19(12):1225–32.PubMedCrossRefGoogle Scholar
  61. 61.
    Eussen SR, Bouvy ML, Rompelberg CJ, et al. Influence of the use of functional foods enriched with phytosterols/-stanols on adherence to statin therapy. Pharmacoepidemiol Drug Saf. 2011;20(8):830–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Iakoubova OA, Tong CH, Rowland CM, et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 2008;51(4):435–43.PubMedCrossRefGoogle Scholar
  63. 63.
    Shiffman D, Chasman DI, Zee RY, et al. A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study. J Am Coll Cardiol. 2008;51(4):444–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Iakoubova OA, Sabatine MS, Rowland CM, et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2008;51(4):449–55.PubMedCrossRefGoogle Scholar
  65. 65.
    • Charland S, Agatep B, Schrader B, et al. Abstract 290: Statin Adherence in Males and Females, and the Impact of Knowledge of a Genetic Test: Results from the AKROBATS Trial. Circulation: Cardiovascular Quality and Outcomes 2012;5(Supplement 1). The utility of pharmacogenetic information to increase adherence was tested, and knowledge of kif6 carrier status increased adherence to statin therapy. Google Scholar
  66. 66.
    •• Kalia N, Li D, Budoff M. Statin Therapy Adherence After Visualizing Coronary Calcium by Cardiac Computed Tomography. J Am Coll Cardiol. 2012;59(13s1):E1188. Increased adherence to statin therapy was achieved by having patients view their arteries lined with calcium on cardiac CT scan.CrossRefGoogle Scholar
  67. 67.
    • Nieuwkerk PT, Nierman MC, Vissers MN, et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. Am J Cardiol. 2012;110(5):666–72. Counseling patients on their CV risk factors improves adherence to statin therapy.PubMedCrossRefGoogle Scholar
  68. 68.
    Liberman JN, Hutchins DS, Shrank WH, Slezak J, Brennan TA. Adherence to medication under mandatory and voluntary mail benefit designs. Am J Manag Care. 2011;17(7):e260–9.PubMedGoogle Scholar
  69. 69.
    Balu S, Simko RJ, Quimbo RM, Cziraky MJ. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin. 2009;25(11):2765–75.PubMedGoogle Scholar
  70. 70.
    Kamat SA, Bullano MF, Chang CL, Gandhi SK, Cziraky MJ. Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population. Curr Med Res Opin. 2011;27(5):961–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Gaw A, Tolmie E, Lindsay GM. The statin breakthrough—remembering to involve the patient. Cardiovasc Drugs Ther. 2004;18(5):343–4.PubMedCrossRefGoogle Scholar
  72. 72.
    Yilmaz MB, Pinar M, Naharci I, et al. Being well-informed about statin is associated with continuous adherence and reaching targets. Cardiovasc Drugs Ther. 2005;19(6):437–40.PubMedCrossRefGoogle Scholar
  73. 73.
    Casebeer L, Huber C, Bennett N, et al. Improving the physician–patient cardiovascular risk dialogue to improve statin adherence. BMC Fam Pract. 2009;10:48.PubMedCrossRefGoogle Scholar
  74. 74.
    Lin GA, Trujillo L, Frosch DL. Consequences of not respecting patient preferences for cancer screening: opportunity lost. Arch Intern Med. 2012;172(5):393–4.PubMedCrossRefGoogle Scholar
  75. 75.
    O'Malley PG. On motivating patients: a picture, even if worth a thousand words, is not enough. Arch Intern Med. 2012;172(4):309–10.PubMedCrossRefGoogle Scholar
  76. 76.
    Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf. 2007;30(8):669–75.PubMedCrossRefGoogle Scholar
  77. 77.
    Golomb BA, Yang E, Denenberg J, Criqui MH. Statin-associated adverse effects. Circulation. 2003;107:e7028–9.Google Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Patricia Maningat
    • 1
  • Bruce R. Gordon
    • 2
  • Jan L. Breslow
    • 1
  1. 1.The Rockefeller UniversityNew YorkUSA
  2. 2.The Rogosin InstituteNew YorkUSA

Personalised recommendations